Pages that link to "Q36093877"
Jump to navigation
Jump to search
The following pages link to A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal (Q36093877):
Displaying 50 items.
- Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved (Q21129279) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (Q22305681) (← links)
- Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria (Q24541080) (← links)
- Antidepressant discontinuation syndromes (Q28188383) (← links)
- Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs (Q33414008) (← links)
- Depression in adults: drug and physical treatments. (Q33448181) (← links)
- Systematic review and guide to selection of selective serotonin reuptake inhibitors (Q33611926) (← links)
- The role of fluoxetine in the treatment of premenstrual dysphoric disorder (Q33654948) (← links)
- Do antidepressants have any potential to cause addiction? (Q33747180) (← links)
- Pharmacokinetics of selective serotonin reuptake inhibitors (Q33837768) (← links)
- The SSRI discontinuation syndrome (Q34013432) (← links)
- What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors (Q34028944) (← links)
- Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (Q34043285) (← links)
- SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. (Q34067137) (← links)
- Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders (Q34086053) (← links)
- Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression (Q34182008) (← links)
- Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature (Q34201451) (← links)
- Citalopram: a comprehensive review (Q34240991) (← links)
- Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. (Q34557821) (← links)
- Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial (Q34748493) (← links)
- Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review (Q35054424) (← links)
- Incorporating the assessment of abuse liability into the drug discovery and development process (Q35132185) (← links)
- Sexual dysfunction with psychotropic drugs (Q35593993) (← links)
- Death and dependence: current controversies over the selective serotonin reuptake inhibitors (Q35660695) (← links)
- Sleep disruption in critically ill patients--pharmacological considerations (Q35691907) (← links)
- Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001-2004 (Q35827362) (← links)
- Treatment-resistant panic disorder (Q35901886) (← links)
- A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature (Q35977716) (← links)
- Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome (Q36544840) (← links)
- Paroxetine: current status in psychiatry (Q36730643) (← links)
- Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria (Q37692726) (← links)
- Sensory disturbances associated with serotonin reuptake inhibitors: brief review. (Q37725845) (← links)
- Paroxetine for the treatment of depression: a critical update (Q37977501) (← links)
- New insights on the antidepressant discontinuation syndrome. (Q38238790) (← links)
- Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system (Q40843173) (← links)
- Fluoxetine tenth anniversary update: the progress continues (Q41653513) (← links)
- Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders (Q41700932) (← links)
- Risks and Benefits of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression (Q41702163) (← links)
- Hypotension following cardiac surgery associated with paroxetine and mirtazapine withdrawal (Q41882784) (← links)
- Antidepressant discontinuation reactions (Q42756523) (← links)
- Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'. (Q43670028) (← links)
- Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: a case series (Q43692730) (← links)
- Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression (Q43760366) (← links)
- Characteristics of fluvoxamine-induced nausea (Q43812378) (← links)
- Comment: serotonin syndrome induced by fluvoxamine and mirtazapine (Q43856294) (← links)
- Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation (Q43955330) (← links)
- Olanzapine and serotonin toxicity (Q44384307) (← links)
- Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison (Q44511463) (← links)
- Paroxetine withdrawal in a neonate with historical and laboratory confirmation (Q44540892) (← links)
- Discontinuation symptoms associated with nefazodone (Q44761177) (← links)